Ankündigung • Jul 30
UFP Technologies, Inc. to Report Q2, 2026 Results on Aug 03, 2026 UFP Technologies, Inc. announced that they will report Q2, 2026 results After-Market on Aug 03, 2026 Ankündigung • Jun 29
UFP Technologies, Inc.(NasdaqCM:UFPT) dropped from Russell 2000 Dynamic Index UFP Technologies, Inc.(NasdaqCM:UFPT) dropped from Russell 2000 Dynamic Index Live-News • Jun 13
UFP Technologies Unveils New CEO and Adds Board Member to Advance Medical Device Focus UFP Technologies appointed Mitchell C. Rock as Chief Executive Officer effective June 4, 2026, consolidating operational and governance leadership at the company.
Ryan Stafford was named General Counsel, Senior Vice President of Human Resources, and Secretary, succeeding retiring executive Chris Litterio and joining the board as its eighth member.
The board approved significant stock unit and performance share awards for the CEO, General Counsel, and CFO to align management incentives with long-term shareholder value.
These leadership changes point to a focus on strengthening management depth as UFP Technologies pursues its role in the medical device contract development and manufacturing (CDMO) market.
For you, the key consideration is how effectively the new leadership team executes on this direction and whether the equity-based awards support disciplined decision making over the long term. Ankündigung • Jun 11
Ufp Technologies, Inc. Announces Appointment of Mitchell C. Rock to the Board, Effective June 4, 2026 UFP Technologies, Inc. announced that on June 4, 2026, the Board appointed Mitchell C. Rock to fill the vacancy on the Board created by such increase in Board size. Mr. Rock will serve on the Board until the Company’s next annual stockholder meeting or until his successor has been duly appointed and qualified or until his earlier death, resignation, retirement, disqualification, removal from office or other cause. Ankündigung • Jun 05
UFP Technologies, Inc. Announces Appointment of Ryan Stafford as General Counsel and Senior Vice President of Human Resources, Effective June 4, 2026 UFP Technologies, Inc. announced the appointment of Ryan Stafford as General Counsel and Senior Vice President of Human Resources, effective June 4, 2026. Stafford succeeded Chris Litterio, who retired after having played a pivotal role in the company’s growth. Stafford brought nearly three decades of experience as a senior legal and human resources leader at high-growth, publicly traded companies, leading Legal and Human Resources and overseeing M&A as well as helping guide corporate growth through both acquisition execution and organizational development. Most recently, Stafford served as Executive Vice President, Chief Legal Officer, Corporate Secretary, and head of Mergers & Acquisitions at Littelfuse, Inc. He joined Littelfuse in 2007 as General Counsel and Vice President of Human Resources, later advancing to Senior Vice President and Chief Legal and Human Resources from 2014 to 2021. In 2021, he was named Executive Vice President, Mergers & Acquisitions and Chief Legal Officer, where he led the company’s acquisition strategy. Prior to Littelfuse, Stafford held senior legal and operational roles at Tyco International Ltd., including Vice President & General Counsel for Tyco Engineered Products & Services and Vice President of China Operations for the segment. He began his legal career as an associate at Sulloway & Hollis, a New Hampshire law firm. Stafford earned a Bachelor of Arts in History and German from Bowdoin College and a Juris Doctor from the University of Maine School of Law. Ankündigung • May 27
UFP Technologies, Inc. Announces Retirement of Christopher P. Litterio from General Counsel, Secretary, and Senior Vice President of Human Resources UFP Technologies, Inc. announced that on May 19, 2026, Christopher P. Litterio, General Counsel, Secretary, and Senior Vice President of Human Resources, informed the company that he planned to retire from the company after a period of transition. Recent Insider Transactions • May 17
Lead Independent Director recently sold US$635k worth of stock On the 12th of May, Daniel Croteau sold around 3k shares on-market at roughly US$222 per share. This transaction amounted to 77% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of US$1.7m more than they bought in the last 12 months. Recent Insider Transactions Derivative • May 14
Lead Independent Director notifies of intention to sell stock Daniel Croteau intends to sell 3k shares in the next 90 days after lodging an Intent To Sell Form on the 12th of May. If the sale is conducted around the recent share price of US$222, it would amount to US$635k. Since June 2025, Daniel's direct individual holding has decreased from 1.79k shares to 230.00. Company insiders have collectively sold US$999k more than they bought, via options and on-market transactions in the last 12 months. Reported Earnings • May 06
First quarter 2026 earnings: EPS exceeds analyst expectations First quarter 2026 results: EPS: US$2.27 (up from US$2.24 in 1Q 2025). Revenue: US$154.2m (up 4.1% from 1Q 2025). Net income: US$17.5m (up 1.8% from 1Q 2025). Profit margin: 11% (in line with 1Q 2025). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 4.8%. Revenue is forecast to grow 6.1% p.a. on average during the next 3 years, compared to a 8.0% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 16% per year whereas the company’s share price has increased by 14% per year. Live-News • May 05
UFP Technologies Grows Medical Revenue and Expands Facilities as New CEO Prepares to Take Over Q1 2026 revenue grew 4.1%, with medical sales up 5.9% and non-medical sales down 15%, reflecting continued focus on healthcare customers. Non-GAAP EPS came in at $2.48, 7.4% above analyst expectations, with an adjusted operating margin of 16.9% in line with the prior year.
The company is adding manufacturing capacity in the Dominican Republic and planning further expansion in Asia-Pacific, while four new medical programs are expected to lift revenue in the second half of 2026. A CEO transition to Mitch Rock is set for June, and management reported that a February 2026 cyber incident and reduced tariff impacts have not had a material effect on operations or financials.
The combination of steady margins, capacity build-out and new medical programs indicates that management is prioritizing higher-value MedTech opportunities over more cyclical non-medical markets.
Investors may want to watch execution on the new facilities and leadership transition, as well as the ramp of those medical programs, since delays or higher start-up costs could weigh on profitability in the near term. Ankündigung • May 04
UFP Technologies, Inc., Annual General Meeting, Jun 04, 2026 UFP Technologies, Inc., Annual General Meeting, Jun 04, 2026. Ankündigung • May 01
UFP Technologies, Inc. to Report Q1, 2026 Results on May 04, 2026 UFP Technologies, Inc. announced that they will report Q1, 2026 results at 4:00 PM, US Eastern Standard Time on May 04, 2026 Reported Earnings • Feb 25
Full year 2025 earnings: EPS misses analyst expectations Full year 2025 results: EPS: US$8.87 (up from US$7.69 in FY 2024). Revenue: US$602.8m (up 20% from FY 2024). Net income: US$68.3m (up 16% from FY 2024). Profit margin: 11% (in line with FY 2024). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 1.3%. Revenue is forecast to grow 5.2% p.a. on average during the next 2 years, compared to a 7.7% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has increased by 27% per year, which means it is tracking significantly ahead of earnings growth. Ankündigung • Feb 20
UFP Technologies, Inc. to Report Q4, 2025 Results on Feb 24, 2026 UFP Technologies, Inc. announced that they will report Q4, 2025 results After-Market on Feb 24, 2026 Valuation Update With 7 Day Price Move • Jan 08
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to US$255, the stock trades at a forward P/E ratio of 27x. Average trailing P/E is 31x in the Medical Equipment industry in the US. Total returns to shareholders of 119% over the past three years. Recent Insider Transactions • Nov 14
General Counsel recently sold US$416k worth of stock On the 6th of November, Christopher Litterio sold around 2k shares on-market at roughly US$227 per share. This transaction amounted to 20% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth US$592k. Insiders have been net sellers, collectively disposing of US$2.8m more than they bought in the last 12 months. Recent Insider Transactions Derivative • Nov 06
General Counsel notifies of intention to sell stock Christopher Litterio intends to sell 2k shares in the next 90 days after lodging an Intent To Sell Form on the 6th of November. If the sale is conducted around the recent share price of US$233, it would amount to US$426k. Since March 2025, Christopher's direct individual holding has decreased from 10.38k shares to 9.32k. Company insiders have collectively sold US$18m more than they bought, via options and on-market transactions in the last 12 months. Reported Earnings • Nov 04
Third quarter 2025 earnings: EPS and revenues exceed analyst expectations Third quarter 2025 results: EPS: US$2.12. Revenue: US$154.6m (up 6.5% from 3Q 2024). Net income: US$16.4m (flat on 3Q 2024). Profit margin: 11% (in line with 3Q 2024). Revenue exceeded analyst estimates by 3.3%. Earnings per share (EPS) also surpassed analyst estimates by 3.8%. Revenue is forecast to grow 5.6% p.a. on average during the next 3 years, compared to a 8.4% growth forecast for the Medical Equipment industry in the US. Ankündigung • Oct 29
UFP Technologies, Inc. to Report Q3, 2025 Results on Nov 03, 2025 UFP Technologies, Inc. announced that they will report Q3, 2025 results After-Market on Nov 03, 2025 Recent Insider Transactions • Sep 10
Lead Independent Director recently sold US$592k worth of stock On the 5th of September, Daniel Croteau sold around 3k shares on-market at roughly US$206 per share. This transaction amounted to 93% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of US$17m more than they bought in the last 12 months. Buy Or Sell Opportunity • Aug 06
Now 26% undervalued after recent price drop Over the last 90 days, the stock has fallen 8.7% to US$214. The fair value is estimated to be US$289, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 21% over the last 3 years. Earnings per share has grown by 23%. Revenue is forecast to grow by 12% in 2 years. Earnings are forecast to grow by 27% in the next 2 years. Reported Earnings • Aug 05
Second quarter 2025 earnings: EPS exceeds analyst expectations Second quarter 2025 results: EPS: US$2.23 (up from US$1.77 in 2Q 2024). Revenue: US$151.2m (up 37% from 2Q 2024). Net income: US$17.2m (up 27% from 2Q 2024). Profit margin: 11% (in line with 2Q 2024). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 5.0%. Revenue is forecast to grow 5.2% p.a. on average during the next 3 years, compared to a 8.2% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has increased by 40% per year, which means it is tracking significantly ahead of earnings growth. Ankündigung • Jul 30
UFP Technologies, Inc. to Report Q2, 2025 Results on Aug 04, 2025 UFP Technologies, Inc. announced that they will report Q2, 2025 results After-Market on Aug 04, 2025 Ankündigung • Jul 17
UFP Technologies, Inc. (NasdaqCM:UFPT) acquired Techno Plastics Industries, Inc. from a group of shareholders for $4.5 million. UFP Technologies, Inc. (NasdaqCM:UFPT) entered into securities purchase agreement to acquire Techno Plastics Industries, Inc. from a group of shareholders for $4.5 million on July 7, 2025. A cash consideration of $4.5 million will be paid by UFP Technologies, Inc. towards common equity of Techno Plastics Industries, Inc. The transaction were financed with available cash and borrowings under UFP’s existing credit facility.
For the period ending December 31, 2024, Techno Plastics Industries, Inc. reported total revenue of approximately $10 million and EBITDA of $1 million.
UFP Technologies, Inc. (NasdaqCM:UFPT) completed the acquisition of Techno Plastics Industries, Inc. from a group of shareholders on July 17, 2025. Buy Or Sell Opportunity • Jul 07
Now 21% undervalued Over the last 90 days, the stock has risen 25% to US$241. The fair value is estimated to be US$306, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 22% over the last 3 years. Earnings per share has grown by 28%. Revenue is forecast to grow by 18% in 2 years. Earnings are forecast to grow by 29% in the next 2 years. Board Change • Jul 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 5 highly experienced directors. Independent Director John Hassett was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Buy Or Sell Opportunity • Jun 13
Now 20% undervalued Over the last 90 days, the stock has risen 11% to US$233. The fair value is estimated to be US$292, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 22% over the last 3 years. Earnings per share has grown by 28%. Revenue is forecast to grow by 18% in 2 years. Earnings are forecast to grow by 29% in the next 2 years. Buy Or Sell Opportunity • May 21
Now 20% undervalued after recent price drop Over the last 90 days, the stock has fallen 14% to US$229. The fair value is estimated to be US$288, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 22% over the last 3 years. Earnings per share has grown by 28%. Revenue is forecast to grow by 18% in 2 years. Earnings are forecast to grow by 29% in the next 2 years. Recent Insider Transactions • May 14
General Counsel recently sold US$324k worth of stock On the 8th of May, Christopher Litterio sold around 1k shares on-market at roughly US$220 per share. This transaction amounted to 14% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth US$1.6m. Insiders have been net sellers, collectively disposing of US$50m more than they bought in the last 12 months. Valuation Update With 7 Day Price Move • May 13
Investor sentiment improves as stock rises 24% After last week's 24% share price gain to US$244, the stock trades at a forward P/E ratio of 28x. Average trailing P/E is 31x in the Medical Equipment industry in the US. Total returns to shareholders of 221% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at US$292 per share. Price Target Changed • May 07
Price target decreased by 18% to US$311 Down from US$379, the current price target is an average from 2 analysts. New target price is 42% above last closing price of US$220. Stock is down 13% over the past year. The company is forecast to post earnings per share of US$8.50 for next year compared to US$7.69 last year. Reported Earnings • May 06
First quarter 2025 earnings: EPS and revenues exceed analyst expectations First quarter 2025 results: EPS: US$2.24 (up from US$1.66 in 1Q 2024). Revenue: US$148.1m (up 41% from 1Q 2024). Net income: US$17.2m (up 35% from 1Q 2024). Profit margin: 12% (in line with 1Q 2024). Revenue exceeded analyst estimates by 5.9%. Earnings per share (EPS) also surpassed analyst estimates by 17%. Revenue is forecast to grow 7.9% p.a. on average during the next 3 years, compared to a 8.1% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has increased by 45% per year, which means it is tracking significantly ahead of earnings growth. Ankündigung • May 01
UFP Technologies, Inc., Annual General Meeting, Jun 04, 2025 UFP Technologies, Inc., Annual General Meeting, Jun 04, 2025. Ankündigung • Apr 30
UFP Technologies, Inc. to Report Q1, 2025 Results on May 06, 2025 UFP Technologies, Inc. announced that they will report Q1, 2025 results Pre-Market on May 06, 2025 Recent Insider Transactions Derivative • Mar 09
Independent Director notifies of intention to sell stock Cynthia Feldmann intends to sell 3k shares in the next 90 days after lodging an Intent To Sell Form on the 28th of February. If the sale is conducted around the recent share price of US$231, it would amount to US$636k. Since June 2024, Cynthia's direct individual holding has decreased from 4.47k shares to 3.82k. Company insiders have collectively sold US$50m more than they bought, via options and on-market transactions in the last 12 months. Recent Insider Transactions • Mar 05
Lead Independent Director recently sold US$1.6m worth of stock On the 27th of February, Daniel Croteau sold around 7k shares on-market at roughly US$228 per share. This transaction amounted to 81% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of US$50m more than they bought in the last 12 months. Recent Insider Transactions Derivative • Feb 28
Lead Independent Director notifies of intention to sell stock Daniel Croteau intends to sell 7k shares in the next 90 days after lodging an Intent To Sell Form on the 27th of February. If the sale is conducted around the recent share price of US$228, it would amount to US$1.6m. Since June 2024, Daniel has owned 8.40k shares directly. Company insiders have collectively sold US$49m more than they bought, via options and on-market transactions in the last 12 months. Reported Earnings • Feb 25
Full year 2024 earnings: EPS exceeds analyst expectations Full year 2024 results: EPS: US$7.69 (up from US$5.89 in FY 2023). Revenue: US$504.4m (up 26% from FY 2023). Net income: US$59.0m (up 31% from FY 2023). Profit margin: 12% (in line with FY 2023). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 1.5%. Revenue is forecast to grow 12% p.a. on average during the next 2 years, compared to a 7.9% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has increased by 58% per year, which means it is tracking significantly ahead of earnings growth. Ankündigung • Feb 19
UFP Technologies, Inc. to Report Q4, 2024 Results on Feb 25, 2025 UFP Technologies, Inc. announced that they will report Q4, 2024 results on Feb 25, 2025 Valuation Update With 7 Day Price Move • Dec 18
Investor sentiment deteriorates as stock falls 18% After last week's 18% share price decline to US$242, the stock trades at a forward P/E ratio of 29x. Average trailing P/E is 36x in the Medical Equipment industry in the US. Total returns to shareholders of 264% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at US$178 per share. Valuation Update With 7 Day Price Move • Nov 20
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to US$290, the stock trades at a forward P/E ratio of 35x. Average trailing P/E is 36x in the Medical Equipment industry in the US. Total returns to shareholders of 303% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at US$180 per share. Recent Insider Transactions • Nov 14
CEO & Chairman recently sold US$8.8m worth of stock On the 11th of November, R. Bailly sold around 25k shares on-market at roughly US$348 per share. This transaction amounted to 14% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger sale worth US$14m. R. has been a net seller over the last 12 months, reducing personal holdings by US$53m. Recent Insider Transactions Derivative • Nov 13
Independent Director notifies of intention to sell stock Symeria Hudson intends to sell 2k shares in the next 90 days after lodging an Intent To Sell Form on the 11th of November. If the sale is conducted around the recent share price of US$341, it would amount to US$782k. Since June 2024, Symeria has owned 945.00 shares directly. Company insiders have collectively sold US$52m more than they bought, via options and on-market transactions in the last 12 months. Reported Earnings • Nov 05
Third quarter 2024 earnings: EPS and revenues exceed analyst expectations Third quarter 2024 results: EPS: US$2.13 (up from US$1.53 in 3Q 2023). Revenue: US$145.2m (up 44% from 3Q 2023). Net income: US$16.4m (up 40% from 3Q 2023). Profit margin: 11% (in line with 3Q 2023). Revenue exceeded analyst estimates by 9.6%. Earnings per share (EPS) also surpassed analyst estimates by 17%. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 8.2% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 35% per year but the company’s share price has increased by 71% per year, which means it is tracking significantly ahead of earnings growth. Valuation Update With 7 Day Price Move • Sep 19
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to US$355, the stock trades at a forward P/E ratio of 46x. Average trailing P/E is 40x in the Medical Equipment industry in the US. Total returns to shareholders of 465% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at US$538 per share. Ankündigung • Aug 27
UFP Technologies, Inc. (NasdaqCM:UFPT) acquired AQF Ltd for €43 million. UFP Technologies, Inc. (NasdaqCM:UFPT) entered into a share purchase agreement to acquire AQF Ltd for €43 million on August 23, 2024. The shares were acquired for an aggregate purchase price of €43.0 million in cash. The aggregate purchase price at closing was approximately 12.3 times AQF Medical’s adjusted net income before interest, taxes, depreciation and amortization for the 12-month period ended June 30, 2024.
UFP Technologies, Inc. (NasdaqCM:UFPT) completed the acquisition of AQF Ltd on August 26, 2024. Recent Insider Transactions • Aug 08
CFO, Senior VP & Treasurer recently sold US$4.0m worth of stock On the 6th of August, Ronald Lataille sold around 13k shares on-market at roughly US$304 per share. This transaction amounted to 22% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Ronald has been a net seller over the last 12 months, reducing personal holdings by US$4.0m. Reported Earnings • Aug 01
Second quarter 2024 earnings: EPS and revenues exceed analyst expectations Second quarter 2024 results: EPS: US$1.77 (up from US$1.56 in 2Q 2023). Revenue: US$110.2m (up 10% from 2Q 2023). Net income: US$13.6m (up 14% from 2Q 2023). Profit margin: 12% (in line with 2Q 2023). Revenue exceeded analyst estimates by 3.0%. Earnings per share (EPS) also surpassed analyst estimates by 15%. Revenue is forecast to grow 20% p.a. on average during the next 2 years, compared to a 8.2% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 39% per year but the company’s share price has increased by 67% per year, which means it is tracking significantly ahead of earnings growth. Price Target Changed • Jul 02
Price target increased by 19% to US$312 Up from US$263, the current price target is an average from 2 analysts. New target price is 10.0% above last closing price of US$284. Stock is up 44% over the past year. The company is forecast to post earnings per share of US$6.74 for next year compared to US$5.89 last year. Valuation Update With 7 Day Price Move • May 08
Investor sentiment improves as stock rises 23% After last week's 23% share price gain to US$253, the stock trades at a forward P/E ratio of 37x. Average trailing P/E is 38x in the Medical Equipment industry in the US. Total returns to shareholders of 352% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at US$105 per share. Major Estimate Revision • May 08
Consensus EPS estimates increase by 12% The consensus outlook for earnings per share (EPS) in fiscal year 2024 has improved. 2024 revenue forecast increased from US$431.7m to US$438.0m. EPS estimate increased from US$5.93 to US$6.62 per share. Net income forecast to grow 11% next year vs 18% growth forecast for Medical Equipment industry in the US. Consensus price target up from US$243 to US$263. Share price rose 23% to US$253 over the past week. Reported Earnings • May 01
First quarter 2024 earnings: EPS and revenues exceed analyst expectations First quarter 2024 results: EPS: US$1.66 (up from US$1.28 in 1Q 2023). Revenue: US$105.0m (up 7.4% from 1Q 2023). Net income: US$12.7m (up 30% from 1Q 2023). Profit margin: 12% (up from 10.0% in 1Q 2023). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 7.9%. Earnings per share (EPS) also surpassed analyst estimates by 50%. Revenue is forecast to grow 9.0% p.a. on average during the next 2 years, compared to a 8.1% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 44% per year but the company’s share price has increased by 63% per year, which means it is tracking significantly ahead of earnings growth. Ankündigung • Apr 29
UFP Technologies, Inc., Annual General Meeting, Jun 05, 2024 UFP Technologies, Inc., Annual General Meeting, Jun 05, 2024, at 10:00 US Eastern Standard Time. Agenda: To elect the seven directors identified as standing for election in the accompanying proxy statement, each to serve until the 2025 Annual Meeting of Stockholders and until their successors are duly elected; to vote on a non binding advisory resolution to approve the compensation of named executive officers; to ratify the appointment of Grant Thornton LLP as independent registered public accounting firm for the fiscal year ended December 31, 2024; and to transact such other business as may properly come before the 2024 Annual Meeting of Stockholders, and at any adjournment or postponement thereof. Valuation Update With 7 Day Price Move • Mar 20
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to US$226, the stock trades at a forward P/E ratio of 38x. Average trailing P/E is 40x in the Medical Equipment industry in the US. Total returns to shareholders of 355% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at US$329 per share. Recent Insider Transactions Derivative • Mar 13
VP & COO of MedTech notifies of intention to sell stock Steven Cardin intends to sell 2k shares in the next 90 days after lodging an Intent To Sell Form on the 11th of March. If the sale is conducted around the recent share price of US$198, it would amount to US$484k. Since June 2023, Steven has owned 2.44k shares directly. Company insiders have collectively sold US$27m more than they bought, via options and on-market transactions in the last 12 months. Recent Insider Transactions • Mar 03
CEO & Chairman recently sold US$5.7m worth of stock On the 23rd of February, R. Bailly sold around 27k shares on-market at roughly US$209 per share. This transaction amounted to 9.5% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. R. has been a net seller over the last 12 months, reducing personal holdings by US$20m. Recent Insider Transactions Derivative • Feb 25
Independent Director notifies of intention to sell stock Cynthia Feldmann intends to sell 2k shares in the next 90 days after lodging an Intent To Sell Form on the 22nd of February. If the sale is conducted around the recent share price of US$214, it would amount to US$369k. Since June 2023, Cynthia has owned 4.17k shares directly. Company insiders have collectively sold US$20m more than they bought, via options and on-market transactions in the last 12 months. Price Target Changed • Feb 22
Price target increased by 23% to US$231 Up from US$188, the current price target is provided by 1 analyst. New target price is 7.9% above last closing price of US$214. Stock is up 84% over the past year. The company is forecast to post earnings per share of US$5.77 for next year compared to US$5.89 last year. Reported Earnings • Feb 22
Full year 2023 earnings: EPS exceeds analyst expectations Full year 2023 results: EPS: US$5.89 (up from US$5.53 in FY 2022). Revenue: US$400.1m (up 13% from FY 2022). Net income: US$44.9m (up 7.5% from FY 2022). Profit margin: 11% (in line with FY 2022). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 2.7%. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 7.9% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 47% per year but the company’s share price has increased by 62% per year, which means it is tracking significantly ahead of earnings growth. 